MaxCyte, Inc. (MXCT)

Market Cap	336.47M
Revenue (ttm)	40.69M
Net Income (ttm)	-32.64M
Shares Out	108.19M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	501,071
Open	3.20
Previous Close	3.20
Day's Range	3.10 - 3.24
52-Week Range	3.10 - 7.50
Beta	0.73
Analysts	Buy
Price Target	12.00 (+285.85%)
Earnings Date	Nov 8, 2023

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engin...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 125
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT

Financial Performance

In 2022, MaxCyte's revenue was $44.26 million, an increase of 30.59% compared to the previous year's $33.89 million. Losses were -$23.57 million, 23.5% more than in 2021.

Analyst Forecast

According to one analyst, the rating for MXCT stock is "Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(285.85% upside)

Analyst Consensus: Buy